Mepraz

Omeprazole, the active ingredient in Mepraz, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces gastric acid production and is used to manage conditions such as gastro‑oesophageal reflux disease, peptic ulcer disease, and Helicobacter pylori infection in adult patients.

GNH USA supplies Mepraz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export.

Omeprazole is indicated for acid‑related disorders affecting the gastrointestinal tract.

Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and esophageal irritation by reducing acid exposure. Peptic ulcer disease: promotes ulcer healing through sustained suppression of gastric acid. Helicobacter pylori eradication regimens: enhances antibiotic efficacy by creating a less acidic gastric environment. Erosive oesophagitis: facilitates mucosal recovery by limiting acid‑mediated damage.

Omeprazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: discomfort in the upper abdomen. - Diarrhoea: loose stools occurring intermittently. - Nausea: feeling of queasiness. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis): rash, swelling, difficulty breathing. - Clostridioides difficile infection: severe colitis with watery diarrhoea. - Hypomagnesemia: low serum magnesium with muscle cramps or arrhythmia. - Elevated liver enzymes: potential hepatic injury. - Stevens‑Johnson syndrome: severe skin blistering. - Interstitial nephritis: kidney inflammation presenting with reduced urine output.

When prescribing omeprazole, clinicians should consider several precautionary measures to ensure safe use.

Renal function: assess in patients with severe kidney disease. Hepatic impairment: use with caution in moderate to severe liver disease. Electrolyte monitoring: check magnesium levels during prolonged therapy. Pregnancy and lactation: risk unknown; prescribe only if benefit outweighs potential risk. Drug interactions: review concomitant medications for possible interactions. Store at room temperature: keep in original container, protect from moisture.

Omeprazole can affect the pharmacokinetics of several medicines; awareness of key interactions helps avoid therapeutic failures.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect. - Atazanavir: markedly decreased antiviral exposure. - HIV protease inhibitors (e.g., ritonavir): diminished efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR. - Digoxin: elevated serum concentrations.